Skip to main content
OpenTrials
Completed

NCT Number: NCT04661124

Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position

This is a prospective clinical study conducted at one clinical site in the United States.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke Eye Center

Durham, North Carolina, 27705, United States

About this study

The conducted study is an observational study for an imaging device used in the aid of ophthalmology diagnosis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Adult Normal Eyes Population (AN)

Inclusion criteria

for AN Population

  • Age ≥ 22 years
  • Able and willing to undergo the test procedures, sign informed consent, and follow instructions.
  • Physically able to be positioned in all required imaging positions (upright at chinrest and supine).
  • Able to fixate.
  • Best corrected visual acuity ≥ 20/40 in both eyes.

Exclusion criteria

for AN Population

  • Eye with ocular media not sufficiently clear to obtain acceptable study-related imaging.
  • Subjects who cannot tolerate the imaging procedures.
  • Clinically significant ocular disease in either eye as determined by an Investigator.
  • Ocular surgical intervention (except for refractive laser surgery or cataract surgery) in either eye.

Adult Posterior Segment Abnormality Eye Population (AD)

Inclusion criteria

for AD Population

  • Age ≥ 22 years
  • Able and willing to undergo the test procedures, sign informed consent, and follow instructions.
  • Physically able to be positioned in all required imaging positions (upright at chinrest and supine).
  • Able to fixate.
  • Eye with a structural and vascular posterior segment abnormality due to ocular disease and/or trauma.

Exclusion criteria

for AD Population

  • Eye with ocular media not sufficiently clear to obtain acceptable study-related imaging.
  • Subjects who cannot tolerate the imaging procedures.

Treatment and study plan

SPECTRALIS

Device

ophthalmic imaging device with head and chinrest

Other names: SPECTRALIS HRA+OCT (and variants) with OCT Angiography Module

SPECTRALIS with Flex Module

Device

ophthalmic imaging device on mobile instrumentation stand

Other names: SPECTRALIS HRA+OCT (and variants) with Flex Module

Primary outcomes

  1. The image quality grade of the acquired images as determined by an independent reading center

    Time frame: through study completion, average of 1 day

    OCT, OCTA and IR cSLO - graded Good (2)/Average (1)/Poor (0)

  2. Agreement in identification of abnormalities of the acquired Standard OCT images between the devices

    Time frame: through study completion, average of 1 day

    based on pre-specified abnormalities

  3. Agreement in identification of abnormalities of the acquired OCTA images between the devices

    Time frame: through study completion, average of 1 day

    based on pre-specified abnormalities

Secondary outcomes

  1. Adverse events

    Time frame: through study completion, average of 1 day

    All AEs

Sponsors and collaborators

Lead sponsor

Heidelberg Engineering GmbH

Industry

Collaborators

  • Duke University

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2024
First posted
Dec 10, 2020
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.